Discusses the molecular characterization of defective antigen processing in human prostate cancer. Analysis of class I major histocompatibility complex (I MHC) assembly in prostate cancer cells; Evaluation of the potential immune resistance pathways; Efficacy of gene-modified tumor vaccines.